Alpha Tau Medical Ltd. (DRTS) Stock Forecast
DRTS analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.40 / 5 from 5 analysts
- Price target
- $17.80 average of analyst targets
- Upside to target
- +44.8% from the latest close
- Next earnings
- November 19, 2026 EPS estimate $-0.14
- 52-week range
- $3.47 – $15.50
DRTS analyst ratings
5 analystsNumber of analysts at each rating.
DRTS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DRTS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.16 | −$0.13 | −$0.14 | −4.8% | 4 |
| Current fiscal year (2026) | −$0.96 | −$1.08 | −$0.55 | −$0.53 | −80.3% | 5 |
| Next fiscal year (2027) | −$0.53 | −$0.60 | −$0.50 | −$0.96 | +44.0% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DRTS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $324,330 | $0 | $500,000 | 0.0% | 3 |
| Current fiscal year (2026) | $944,330 | $0 | $1.5M | 0.0% | 3 |
| Next fiscal year (2027) | $12.6M | $0 | $30.3M | +1,235.6% | 4 |
DRTS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DRTS revenue: reported and forecast
DRTS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −$0.15 | +6.1% | 1 up · 3 down |
| Current fiscal year (2026) | −$0.66 | −$0.66 | −$0.66 | −$0.88 | −$0.96 | +45.1% | 1 up · 4 down |
| Next fiscal year (2027) | −$0.51 | −$0.51 | −$0.51 | −$0.53 | −$0.53 | +3.9% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DRTS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DRTS beat in 6 of 12.
What analysts expect from DRTS
5 analysts cover Alpha Tau Medical; their consensus rating is buy (4.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.80, 44.8% above the latest close of $12.29. Analysts expect earnings of −$0.96 per share for 2026, −80.3% from a year earlier. For 2027 the average estimate is −$0.53 per share on revenue of $12.6 million. Alpha Tau Medical beat the EPS estimate in 6 of the last 12 quarters.
Related: DRTS income statement, DRTS key metrics, DRTS chart. See the DRTS stock overview for the latest quote and news.
DRTS forecast FAQ
What is Alpha Tau Medical's price target?
The average analyst price target for Alpha Tau Medical is $17.80, 44.8% above the latest close of $12.29.
Is Alpha Tau Medical a buy, hold or sell?
Of 5 analysts covering Alpha Tau Medical, 3 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Alpha Tau Medical's EPS forecast?
Analysts forecast −$0.96 per share for 2026 (range −$1.08 to −$0.55); for 2027 the estimate is −$0.53.
What is Alpha Tau Medical's revenue forecast?
The average revenue estimate for 2026 is $0.9 million, growth of 0.0%; for 2027 it is $12.6 million.
When does Alpha Tau Medical report earnings?
Alpha Tau Medical is expected to report results for the quarter ending September 30, 2026 on November 19, 2026 after the market closes; the EPS estimate is $-0.14.
Does Alpha Tau Medical usually beat earnings estimates?
Alpha Tau Medical reported EPS at or above the analyst estimate in 6 of the last 12 quarters.